Takeda Pharmaceutical Co Ltd - Nov 30, 2022 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Role
10%+ Owner
Signature
/s/ Yoshihiro Nakagawa, Global General Counsel of Takeda Pharmaceutical Company Limited
Stock symbol
HLVX
Transactions as of
Nov 30, 2022
Transactions value $
$0
Form type
4
Date filed
12/1/2022, 04:47 PM
Previous filing
Jul 6, 2022
Next filing
May 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HLVX Common Stock Exercise of in-the-money or at-the-money derivative security $0 +5.88M +700% $0.00 6.72M Nov 30, 2022 See Explanation of Responses F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HLVX Warrant (Right to Buy) Exercise of in-the-money or at-the-money derivative security $0 -5.88M -100% $0.00* 0 Nov 30, 2022 Common Stock 5.88M $0.00 See Explanation of Responses F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 30,2022, the Reporting Person exercised a Warrant to purchase 5,883,500 shares of the Issuers common stock with an exercise price of $0.0000595 per share.
F2 Takeda Pharmaceutical Company Limited has beneficial ownership of the reported securities, all of which are held directly by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of TakedaPharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) andTakeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.